Amylyx Pharmaceuticals, Inc. - Laporan Laba Rugi (TTM)

Amylyx Pharmaceuticals, Inc.

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Amylyx Pharmaceuticals, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
12-31
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 1 1 0 0 0 0 22 94 192 294 381 398 299 196 87 -1 -0
Change (%) -2.31 -55.12 0.00 0.00 21.05 6,343.48 321.31 104.87 53.34 29.42 4.52 -24.93 -34.23 -55.53 -101.46 -80.42
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 25 36 44 38 72 18 96 102 115 125 154 277 273 296 229 98 94
Change (%) 44.99 23.50 -13.03 87.91 -75.59 449.00 6.27 12.03 8.86 22.91 80.41 -1.39 8.41 -22.81 -57.23 -3.63
% of Revenue 3,783.69 5,615.59 15,452.63 13,438.95 25,252.63 5,091.88 433.84 109.43 59.84 42.48 40.34 69.64 91.48 150.80 261.78 -7,690.41 -37,861.04
Gross Operating Profit -24 -35 -44 -38 -72 -17 -74 -9 77 169 227 121 25 -100 -141 -99 -95
Change (%) 46.27 24.93 -13.12 88.57 -75.98 330.92 -88.10 -972.25 119.63 34.23 -46.81 -78.93 -492.15 41.61 -29.89 -4.61
% of Revenue -3,683.69 -5,515.59 -15,352.63 -13,338.95 -25,152.63 -4,991.88 -333.84 -9.43 40.16 57.52 59.66 30.36 8.52 -50.80 -161.78 7,790.41 37,961.04
SG&A 15 28 39 59 82 101 127 145 158 177 188 202 180 149 114 72 66
Change (%) 85.52 39.34 52.26 37.68 24.00 25.61 13.89 9.25 11.87 6.44 7.30 -10.76 -17.13 -23.51 -36.80 -8.31
% of Revenue 2,317.08 4,400.16 13,660.70 20,799.65 28,636.84 29,334.78 571.88 154.59 82.44 60.14 49.47 50.78 60.37 76.07 130.86 -5,680.50 -26,606.02
R&D 20 67 2 36 36 36
Change (%) 0.00 0.00
% of Revenue 7,136.49 19,314.78 2.09 41.44 -2,846.15 -14,539.36
OpEx 40 64 83 118 154 185 224 249 273 302 342 479 454 446 379 206 197
Change (%) 60.38 30.46 42.12 30.25 20.72 20.58 11.48 9.53 10.60 13.26 40.15 -5.34 -1.74 -14.92 -45.61 -4.63
% of Revenue 6,100.77 10,015.75 29,113.33 41,375.09 53,889.47 53,741.45 1,005.72 266.12 142.28 102.63 89.81 120.42 151.85 226.88 434.07 -16,217.06 -79,006.43
Operating Income -39 -63 -83 -118 -153 -185 -201 -156 -81 -8 39 -81 -155 -249 -292 -208 -197
Change (%) 61.43 31.32 42.26 30.32 20.72 8.80 -22.73 -47.86 -90.48 -602.29 -309.46 90.60 60.93 17.08 -28.89 -5.10
% of Revenue -6,000.77 -9,915.75 -29,013.33 -41,275.09 -53,789.47 -53,641.45 -905.72 -166.12 -42.28 -2.63 10.19 -20.42 -51.85 -126.88 -334.07 16,317.06 79,106.43
Interest Expense -2 -0
Change (%) -99.96
% of Revenue -352.00 -0.16
Net Income -42 -68 -88 -121 -153 -184 -198 -149 -73 2 49 -71 -166 -259 -302 -219 -188
Change (%) 61.26 28.97 37.90 26.51 19.96 7.80 -24.91 -51.12 -102.52 2,583.61 -244.29 133.31 56.43 16.29 -27.47 -14.28
% of Revenue -6,504.62 -10,736.85 -30,852.98 -42,545.96 -53,824.91 -53,337.68 -892.38 -159.04 -37.95 0.62 12.94 -17.86 -55.52 -132.05 -345.36 17,205.74 75,341.37

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista